Drug intelligence / Profile preview

Skyvit+

Development stage: Unknown
Lead developer: Skyways Healthcare
Modality: Small Molecules
Administration: Oral

Overview

Skyvit+ is a multivitamin and multimineral supplement developed and marketed by Skyways Healthcare, an Indian pharmaceutical company. It is a branded generic product sold through the company's PCD (Propaganda Cum Distribution) franchise model. The formulation is designed to address nutritional deficiencies and support overall metabolic health by providing essential micronutrients that serve as vital cofactors in various physiological processes. As part of the Skyvit product line, which includes other variants like Skyvit-B and Skyvit-5G, Skyvit+ is positioned as a general wellness supplement rather than a novel therapeutic candidate. It is currently approved and marketed for oral administration.

Brand names: Skyvit+
Other names: Skyvit Plus

Beyond the preview

Go deeper on Skyvit+.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skyvit+.

Explore the full profile